BMS's brivanib misses OS endpoint in liver cancer

Bristol-Myers Squibb Co. (NYSE:BMY) said brivanib plus best supportive care missed the primary endpoint of overall survival vs. best supportive care alone in the Phase III BRISK-PS trial treat hepatocellular carcinoma. The study enrolled 395 patients who failed treatment with or were intolerant to Nexavar sorafenib. BRISK-PS is one of four Phase III trials of brivanib in different HCC populations. Bristol-Myers expects to complete the BRISK-FL trial of brivanib vs. sorafenib in the first-line setting in 2012.

Brivanib is a dual inhibitor of VEGFR-2 and fibroblast growth factor (FGF) receptor 1 ( FGFR1; CD331). Bayer AG (Xetra:BAY) and Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) market Nexavar sorafenib. ...